MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Tardive dyskinesia(TD)"

  • MDS Virtual Congress 2021

    Evaluation of the QTc prolongation risk of deutetrabenazine

    F. Schneider, B. Darpo, M. Gutierrez, M. Gordon, L. Rabinovich-Guilatt (Ulm, Germany)

    Objective: To assess QTc prolongation risk of deutetrabenazine and its active metabolites by conducting exposure-QTc interval modeling, and to predict QTc prolongation in both CYP2D6…
  • MDS Virtual Congress 2021

    Risk of Tardive Dyskinesia in Patients with Tic Disorders: Preliminary Results

    M. Markota, B. Coombes, J. Leung, R. Savica (Rochester, USA)

    Objective: To determine the relative risk of tardive dyskinesia in patients with tic disorders by comparing three clinical populations: i) patients with tic disorders without…
  • MDS Virtual Congress 2021

    Reanalysis of a Patient-Reported Outcome (Tardive Dyskinesia Impact Scale) Shows Positive Results

    D. Stull, M. Bron, S. Bean, B. Williams, R. Farber, E. Franey, C. Yonan, R. Dhanda (New York, USA)

    Objective: To reanalyze the Tardive Dyskinesia Impact Scale (TDIS) and assess its potential utility in future TD studies. Background: TD is a persistent and potentially…
  • MDS Virtual Congress 2021

    Impacts of Tardive Dyskinesia (TD) Symptoms on Patients: Analysis of a TD-Specific Patient-Reported Outcome

    D. Stull, M. Bron, S. Bean, B. Williams, R. Farber, E. Franey, C. Yonan, R. Dhanda (New York, USA)

    Objective: To understand the impact of tardive dyskinesia (TD) symptoms on patients, confirm the appropriateness of the Tardive Dyskinesia Impact Scale (TDIS) as a patient-reported…
  • MDS Virtual Congress 2021

    Patterns of Improvement with Valbenazine in Patients with Tardive Dyskinesia

    C. Correll, T. Carmack, C. Shah, L. Lundt (Glen Oaks, USA)

    Objective: To characterize different patterns of improvement with valbenazine (VBZ) in patients with tardive dyskinesia (TD) using Abnormal Involuntary Movement Scale (AIMS) data from KINECT…
  • MDS Virtual Congress 2020

    Prospective investigation of the frequency of tardive syndromes in outpatients attending two specialist psychiatry hospitals in Lagos, Nigeria

    E. Campbell, B. Fadipe, O. Ojo, S. Oluwaniyi, N. Okubadejo (Surulere, Nigeria)

    Objective: To determine the frequency and profile of TS in persons on antipsychotics attending tertiary psychiatry hospitals. Background: The term tardive syndrome (TS) encompasses the…
  • MDS Virtual Congress 2020

    Belly dancer’s dyskinesia due to prochlorperazine

    L. Cavdar, S. Ajasin, S. Woolf, R. Fekete (Valhalla, NY, USA)

    Objective: We aim to present a case report of abdominal wall dyskinesia as a tardive syndrome of prochlorperazine. Background: The clinical presentation of involuntary choreiform…
  • MDS Virtual Congress 2020

    Real-World Evaluation of Patient Characteristics and Disease Management in Long-Term Valbenazine Treatment in Adults with Tardive Dyskinesia

    E. Goldberg, C. Yonan, N. Longo, H. Cratty, M. Nicosia, J. Sampalis, T. Carmack, S. Siegert, A. Angelov (San Diego, CA, USA)

    Objective: To assess the clinical characteristics and overall disease management of adult patients receiving long-term valbenazine treatment for tardive dyskinesia (TD) in a real-world setting.…
  • MDS Virtual Congress 2020

    Patient Perspective of Tardive Dyskinesia: Results from a Social Media Listening Study

    L. Lundt, M. Farrar, E. Franey, C. Yonan (San Diego, CA, USA)

    Objective: To use social media listening (SML) to understand the impact of symptoms on patients with assumed/self-reported tardive dyskinesia (TD). Background: TD is a persistent…
  • MDS Virtual Congress 2020

    Real-World Use and Impact of VMAT2 Inhibitors in Patients with Tardive Dyskinesia

    L. Lundt, E. Franey, C. Yonan (San Diego, CA, USA)

    Objective: To describe symptom impact and treatment outcomes in patients prescribed vesicular monoamine 2 (VMAT2) inhibitors for the treatment of tardive dyskinesia (TD). Background: TD,…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 8
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • #25116 (not found)
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley